FDA approves painkiller said to thwart addiction
Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years


What happened
The Food and Drug Administration Thursday approved a new class of pain pill that is not addictive like opioids. Suzetrigine, being sold as Journavx by Vertex Pharmaceuticals, is the first new pharmaceutical treatment for pain to win FDA approval in more than 20 years.
Who said what
Opioids work by binding to receptors in the brain that receive pain signals from nerves around the body, but "those chemical interactions also give rise to opioids' addictive effects," The Associated Press said. But while prescription opioids have helped fuel an epidemic of addiction and overdoses, suzetrigine "works differently," intercepting pain signals before they reach the brain.
In two clinical trials submitted by Vertex, suzetrigine was more effective than a placebo at treating short-term pain in people recovering from stomach and foot surgery, and on par with a combined acetaminophen-hydrocodone pill, like Vicodin.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What next?
Journavx was approved to treat acute pain in adults. But at a list price of $15.50 a pill, it "faces some hurdles in winning over physicians, hospitals and insurance companies," The Washington Post said. The new painkiller is promising because "there are a number of people who, once they have an opioid, want an opioid constantly," University of Washington pain expert Dr. John Loeser said to The New York Times. But acetaminophen-opioid pills are "dirt cheap."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Rafi Schwartz has worked as a politics writer at The Week since 2022, where he covers elections, Congress and the White House. He was previously a contributing writer with Mic focusing largely on politics, a senior writer with Splinter News, a staff writer for Fusion's news lab, and the managing editor of Heeb Magazine, a Jewish life and culture publication. Rafi's work has appeared in Rolling Stone, GOOD and The Forward, among others.
-
Trade war with China threatens U.S. economy
Feature Trump's tariff battle with China is hitting U.S. businesses hard and raising fears of a global recession
By The Week US
-
Corruption: The road to crony capitalism
Feature Trump's tariff pause sent the stock market soaring — was it insider trading?
By The Week US
-
China Shock 2.0
Feature An overflow of Chinese goods is flooding the global market. Tariffs won’t stop it.
By The Week US
-
Hantavirus: the rare pathogen linked to rodents that attacks the lungs
The Explainer Despite the low risk of contracting it, the virus could be potentially deadly
By Theara Coleman, The Week US
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
By Peter Weber, The Week US
-
What does Health and Human Services do?
The Explainer Cuts will 'dramatically alter' public health in America
By Joel Mathis, The Week US
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
By Peter Weber, The Week US
-
Tuberculosis sees a resurgence and is only going to get worse
Under the radar The spread of the deadly infection is buoyed by global unrest
By Devika Rao, The Week US
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
By Peter Weber, The Week US
-
MAHA moms: the cohort of women backing RFK Jr.'s health agenda
The Explainer America's head health honcho has a flock of supporters spreading the MAHA message on social media
By Theara Coleman, The Week US
-
The banned pesticide poisoning Caribbean paradise
Under the radar Martinique and Guadeloupe have been rocked by soaring cancer rates amid other diagnoses
By Rebekah Evans, The Week UK